Intelence

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
28-11-2022
Karakteristik produk Karakteristik produk (SPC)
28-11-2022

Bahan aktif:

Etravirine

Tersedia dari:

Janssen-Cilag International NV

Kode ATC:

J05AG04

INN (Nama Internasional):

etravirine

Kelompok Terapi:

Non-nucleoside reverse transcriptase inhibitors, Antivirals for systemic use

Area terapi:

HIV Infections

Indikasi Terapi:

Intelence, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of human-immunodeficiency-virus-type-1 (HIV-1) infection in antiretroviral-treatment-experienced adult patients and in antiretroviral-treatment-experienced paediatric patients from six years of age.This indication is based on week-48 analyses from two phase-III trials in highly pretreated patients where Intelence was investigated in combination with an optimised background regimen (OBR) which included darunavir/ritonavir. The indication in paediatric patients is based on 48-week analyses of a single-arm, phase-II trial in antiretroviral-treatment-experienced paediatric patients.

Ringkasan produk:

Revision: 30

Status otorisasi:

Authorised

Tanggal Otorisasi:

2008-08-28

Selebaran informasi

                                45
B. PACKAGE LEAFLET
46
PACKAGE LEAFLET: INFORMATION FOR THE USER
INTELENCE 25 MG TABLETS
etravirine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What INTELENCE is and what it is used for
2.
What you need to know before you take INTELENCE
3.
How to take INTELENCE
4.
Possible side effects
5.
How to store INTELENCE
6.
Contents of the pack and other information
1.
WHAT INTELENCE IS AND WHAT IT IS USED FOR
INTELENCE contains the active substance etravirine. INTELENCE belongs
to a group of anti-HIV
medicines called non-nucleoside reverse transcriptase inhibitors
(NNRTIs).
INTELENCE is a medicine used for the treatment of Human
Immunodeficiency Virus (HIV)
infection. INTELENCE works by reducing the amount of HIV in your body.
This will improve your
immune system and reduces the risk of developing illnesses linked to
HIV infection.
INTELENCE is used in combination with other anti-HIV medicines to
treat adults and children
2 years of age and older who are infected by HIV and who have used
other anti-HIV medicines before.
Your doctor will discuss with you which combination of medicines is
best for you.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE INTELENCE
DO NOT TAKE INTELENCE
-
if you are allergic to etravirine or any of the other ingredients of
this medicine (listed in
section 6)
-
if you are taking elbasvir/grazoprevir (a medicine to treat hepatitis
C infection).
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking INTELENCE.
INTELENCE is not a cure for HIV infection. It is part of a t
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
INTELENCE 25 mg tablets
INTELENCE 100 mg tablets
INTELENCE 200 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
INTELENCE 25 mg tablets
Each tablet contains 25 mg of etravirine.
Excipient with known effect
Each tablet contains 40 mg lactose (as monohydrate).
Each tablet contains less than 1 mmol sodium (23 mg), and is
essentially sodium-free.
INTELENCE 100 mg tablets
Each tablet contains 100 mg of etravirine.
Excipient with known effect
Each tablet contains 160 mg lactose (as monohydrate).
Each tablet contains less than 1 mmol sodium (23 mg), and is
essentially sodium-free.
INTELENCE 200 mg tablets
Each tablet contains 200 mg of etravirine.
Excipient with known effect
Each tablet contains less than 1 mmol sodium (23 mg), and is
essentially sodium-free.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
INTELENCE 25 mg tablets
Tablet
White to off-white, oval, scored tablet, debossed with “TMC” on
one side.
The tablet can be divided into two equal doses.
INTELENCE 100 mg tablets
Tablet
White to off-white, oval tablet debossed with “T125” on one side
and “100” on the other side.
INTELENCE 200 mg tablets
Tablet
White to off-white, biconvex, oblong tablet debossed with “T200”
on one side.
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
INTELENCE, in combination with a boosted protease inhibitor and other
antiretroviral medicinal
products, is indicated for the treatment of human immunodeficiency
virus type 1 (HIV-1) infection in
antiretroviral treatment-experienced adult patients and in
antiretroviral treatment-experienced
paediatric patients from 2 years of age (see sections 4.4, 4.5 and
5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Therapy should be initiated by a physician experienced in the
management of HIV infection.
Posology
INTELENCE must always be given in combination with other
antiretroviral medicinal products.
_Adults_
The recommended dose of etravirine for adults is 200 mg (on
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 28-11-2022
Karakteristik produk Karakteristik produk Bulgar 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Bulgar 15-05-2020
Selebaran informasi Selebaran informasi Spanyol 28-11-2022
Karakteristik produk Karakteristik produk Spanyol 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Spanyol 15-05-2020
Selebaran informasi Selebaran informasi Cheska 28-11-2022
Karakteristik produk Karakteristik produk Cheska 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Cheska 15-05-2020
Selebaran informasi Selebaran informasi Dansk 28-11-2022
Karakteristik produk Karakteristik produk Dansk 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Dansk 15-05-2020
Selebaran informasi Selebaran informasi Jerman 28-11-2022
Karakteristik produk Karakteristik produk Jerman 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Jerman 15-05-2020
Selebaran informasi Selebaran informasi Esti 28-11-2022
Karakteristik produk Karakteristik produk Esti 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Esti 15-05-2020
Selebaran informasi Selebaran informasi Yunani 28-11-2022
Karakteristik produk Karakteristik produk Yunani 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Yunani 15-05-2020
Selebaran informasi Selebaran informasi Prancis 28-11-2022
Karakteristik produk Karakteristik produk Prancis 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Prancis 15-05-2020
Selebaran informasi Selebaran informasi Italia 28-11-2022
Karakteristik produk Karakteristik produk Italia 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Italia 15-05-2020
Selebaran informasi Selebaran informasi Latvi 28-11-2022
Karakteristik produk Karakteristik produk Latvi 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Latvi 15-05-2020
Selebaran informasi Selebaran informasi Lituavi 28-11-2022
Karakteristik produk Karakteristik produk Lituavi 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Lituavi 15-05-2020
Selebaran informasi Selebaran informasi Hungaria 28-11-2022
Karakteristik produk Karakteristik produk Hungaria 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Hungaria 15-05-2020
Selebaran informasi Selebaran informasi Malta 28-11-2022
Karakteristik produk Karakteristik produk Malta 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Malta 15-05-2020
Selebaran informasi Selebaran informasi Belanda 28-11-2022
Karakteristik produk Karakteristik produk Belanda 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Belanda 15-05-2020
Selebaran informasi Selebaran informasi Polski 28-11-2022
Karakteristik produk Karakteristik produk Polski 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Polski 15-05-2020
Selebaran informasi Selebaran informasi Portugis 28-11-2022
Karakteristik produk Karakteristik produk Portugis 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Portugis 15-05-2020
Selebaran informasi Selebaran informasi Rumania 28-11-2022
Karakteristik produk Karakteristik produk Rumania 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Rumania 15-05-2020
Selebaran informasi Selebaran informasi Slovak 28-11-2022
Karakteristik produk Karakteristik produk Slovak 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Slovak 15-05-2020
Selebaran informasi Selebaran informasi Sloven 28-11-2022
Karakteristik produk Karakteristik produk Sloven 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Sloven 15-05-2020
Selebaran informasi Selebaran informasi Suomi 28-11-2022
Karakteristik produk Karakteristik produk Suomi 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Suomi 15-05-2020
Selebaran informasi Selebaran informasi Swedia 28-11-2022
Karakteristik produk Karakteristik produk Swedia 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Swedia 15-05-2020
Selebaran informasi Selebaran informasi Norwegia 28-11-2022
Karakteristik produk Karakteristik produk Norwegia 28-11-2022
Selebaran informasi Selebaran informasi Islandia 28-11-2022
Karakteristik produk Karakteristik produk Islandia 28-11-2022
Selebaran informasi Selebaran informasi Kroasia 28-11-2022
Karakteristik produk Karakteristik produk Kroasia 28-11-2022
Laporan Penilaian publik Laporan Penilaian publik Kroasia 15-05-2020

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen